MONIQUE NOYES: Open Payments
NPI 1336394089 · CENTRAL POINT, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$334 in 16 payments from 10 companies in 2025. Trend: 2023 $1,392 · 2024 $628 · 2025 $334
Food & beverage: $318Education: $16
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Lundbeck LLC | 2 | $49 |
| ABBVIE INC. | 2 | $47 |
| GlaxoSmithKline, LLC. | 2 | $44 |
| Novo Nordisk Inc | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Globus Medical, Inc. | 1 | $16 |
Products named: REXULTI, UBRELVY, TRELEGY ELLIPTA, Rybelsus, AIRSUPRA, TRINTELLIX, Kerendia, MOUNJARO.
Industry payments across OR — which companies pay providers there.
